The features of the course of virus-associated acute lung injury in mice with induced immunosuppression

Abstract

BACKGROUND: Among all groups of patients with virus-associated acute lung injury with influenza infection, the most severe course is observed in patients with immunosuppression. In this case, despite the studied mechanism of the course of combined pathology, the question of therapy in this group of patients remains unclear.

AIM: To study the features of the course of acute lung injury in influenza infection with secondary immunosuppression in an experiment for the possibility of searching for experimental therapy for this combined pathology.

MATERIALS AND METHODS: The study was performed on 115 outbred female mice. The mouse-adapted pandemic influenza virus A/California/7/09MA (H1N1)pdm09 was used for modeling viral acute lung injury. Experimental immunosuppression was reproduced by administration of methotrexate (1.25 mg/kg intraperitoneally, once every 3 days during 3 weeks before infection). During the experiment, mortality, blood oxygen saturation, the concentration of pro-inflammatory cytokines in the lungs, and the severity of lung injury were measured.

RESULTS: The presence of experimental immunosuppression led to an exacerbation of acute lung injury in infected animals in terms of mortality and lung damage. Changes in the dynamics of proinflammatory cytokines (TNF-á, IL-6, IL-1â) in the lungs were observed during acute lung injury. Retarded recovery of the lungs functional activity was noted.

CONCLUSIONS: The experimental immunosuppression contributed to the exacerbation of acute lung injury and to an increase in the duration of the pathology. These changes could be associated with an altered process of elimination of the pathogen. The reproduced model of combined pathology was used for searching a therapy for these complications.

Keywords

influenza / acute lung injury / immunosuppression / model

References

[1] Kozhokaru VI, Lobzin YuV, Kozhokaru DI. Intensive therapy of severe complications of influenza. Zurnal infektologii. 2012;4(1):58–64. (In Russ.). DOI: 10.22625/2072-6732-2012-4-1-58-64

[2] Кожокару В.И., Лобзин Ю.В., Кожокару Д.И. Интенсивная терапия тяжелых осложнений гриппа // Журнал инфектологии. 2012. Т. 4, № 1. С. 58–64. DOI: 10.22625/2072-6732-2012-4-1-58-64

[3] Suratt BT, Parsons PE. Mechanisms of acute lung injury/acute respiratory distress syndrome. Clin Chest Med. 2006;27(4):579–589. DOI: 10.1016/j.ccm.2006.06.005

[4] Suratt B.T., Parsons P.E. Mechanisms of acute lung injury/acute respiratory distress syndrome // Clin. Chest. Med. 2006. Vol. 27, No. 4. P. 579–589. DOI: 10.1016/j.ccm.2006.06.005

[5] Harish MM, Ruhatiya RS. Influenza H1N1 infection in immunocompromised host: A concise review. Lung India. 2019;36(4):330–336. DOI: 10.4103/lungindia.lungindia_464_18

[6] Harish M.M., Ruhatiya R.S. Influenza H1N1 infection in immunocompromised host: A concise review // Lung India. 2019. Vol. 36, No. 4. P. 330–336. DOI: 10.4103/lungindia.lungindia_464_18

[7] Cortegiani A, Madotto F, Gregoretti C, et al. Immunocompromised patients with acute respiratory distress syndrome: secondary analysis of the LUNG SAFE database. Crit Care. 2018;22(1):157. DOI: 10.1186/s13054-018-2079-9

[8] Cortegiani A., Madotto F., Gregoretti C. et al. Immunocompromised patients with acute respiratory distress syndrome: secondary analysis of the LUNG SAFE database // Crit. Care. 2018. Vol. 22, No. 1. P. 157. DOI: 10.1186/s13054-018-2079-9

[9] Shitov LN. Vliyanie immunodepressantov na chislennost’ stafilokokkov v sostave mikroflory tolstoj kishki. Modern Problems of Science and Education. 2008;(1):151–152. (In Russ.)

[10] Шитов Л.Н. Влияние иммунодепрессантов на численность стафилококков в составе микрофлоры толстой кишки // Современные проблемы науки и образования. 2008. № 1. С. 151–152.

[11] Matute-Bello G, Downey G, Moore BB, et al. An official American Thoracic Society workshop report: features and measurements of experimental acute lung injury in animals. Am J Respir Cell Mol Biol. 2011;44(5):725–738. DOI: 10.1165/rcmb.2009-0210ST

[12] Matute-Bello G., Downey G., Moore B.B. et al. An official American Thoracic Society workshop report: features and measurements of experimental acute lung injury in animals // Am. J. Respir. Cell. Mol. Biol. 2011. Vol. 44, No. 5. P. 725–738. DOI: 10.1165/rcmb.2009-0210ST

[13] Zheng K, Wu L, He Z, et al. Measurement of the total protein in serum by biuret method with uncertainty evaluation. Measurement. 2017;112:16–21. DOI: 10.1016/j.measurement.2017.08.013

[14] Zheng K., Wu L., He Z. et al. Measurement of the total protein in serum by biuret method with uncertainty evaluation // Measurement. 2017. No. 112. P. 16–21. DOI: 10.1016/j.measurement.2017.08.013

[15] Patel BV, Wilson MR, Takata M. Resolution of acute lung injury and inflammation: a translational mouse model. Eur Respir J. 2011;39(5):1162–1170. DOI: 10.1183/09031936.00093911

[16] Patel B.V., Wilson M.R., Takata M. Resolution of acute lung injury and inflammation: a translational mouse model // Eur. Respir. J. 2011. Vol. 39, No. 5. P. 1162–1170. DOI: 10.1183/09031936.00093911

[17] Spadaro S, Park M, Turrini C, et al. Biomarkers for acute respiratory distress syndrome and prospects for personalised medicine. J Inflamm (Lond). 2019;16:1. DOI: 10.1186/s12950-018-0202-y

[18] Spadaro S., Park M., Turrini C. et al. Biomarkers for acute respiratory distress syndrome and prospects for personalised medicine // J. Inflamm. (Lond). 2019. No. 16. P. 1. DOI: 10.1186/s12950-018-0202-y

[19] Okovityj SV. Klinicheskaya farmakologiya immunodepressantov. Reviews on Clinical Pharmacology and Drug Therapy. 2003;2(2):2–34. (In Russ.)

[20] Оковитый С.В. Клиническая фармакология иммунодепрессантов // Обзоры по клинической фармакологии и лекарственной терапии. 2003. Т. 2, № 2. С. 2–34.

RIGHTS & PERMISSIONS

Aleksandrov A.G.